Contact This Organization
PHAGE stands for the personalized health academy of guided education. We prioritize enabling patients to be shared decision makers so they can advocate for their own health. By doing so we are able to drive patients to accessible treatment options and to be responsive to their health outcomes with the aims of achieving personalized medicine through the lens of access. Beyond our digital health component we are spinning out clinical assets the drive better outcomes for patients in solid tumors.
Healing healthcare by championing evidence based personalized medicine.
Type of Organization
Startup - Newly established businesses, investable
Size of Organization
Organization Mailing Address
424 w 53rd st
New York, NY 10019
In solid tumors there are many opportunities to go off label from existing treatment pathways and still be under standard of care. Being able to help patients with the advent of telehealth and with novel clinical products entering the market on a constant basis will drive the adoption of personalized medicine. In a large class of solid tumors we have produced a digital health solution for patients and caregivers to utilize to navigate their healthcare journey. In a subsection of tumors we will pay for access to diagnostics and treatments to drive health outcomes.
The solid tumors we initially support with our complete comprehensive solution of diagnostic, prognostic, treatment, and digital health falls under the indications squamous cellular carcinoma of the head and neck, non small cell lung carcinoma, triple negative breast cancer, adenocarcinoma, prostate cancer, pancreatic cancer, and colorectal cancer. We support a broader digital health platform that also leans into diffuse hematological malignancies. The patient journey network we have developed guides patients and caregivers through awareness, education, access, options, treatments, caregiving, followup, and outcomes. By being able to help the patients navigate this journey with our without insurance coverage we generate the real world data needed to drive the innovation we have in solid tumors by being able to provide a diagnostic, prognostic, and treatment as well down the road.
Category of Innovation
Life Sciences - Life science solutions are those solutions that are delivered as a drug or device that typically require federal approval
Intended End User
Patient - Individuals who receive health care
Payer - Organizations responsible for issuing or administering payment for the care received by a population of people (e.g. insurance companies)
Problem (i.e. barrier, issue, complication, etc.) being solved for the end user
The end user of the patient and caregiver have difficulty knowing what to do to progress in their healthcare journey and feel unassisted having to exhaust all of the options available. Even when they do an exhaustive review generally health literacy is a barrier and often leaves many stones unturned. We make the journey a bit more approachable as well as providing validated solutions as well.
Idea/solution to the problem, if applicable
For the broader category of solid tumors we are able to support patients through our digital platform to navigate their healthcare journey. For a large percentage of solid tumors, primarily squamous cellular carcinoma of the head and neck, we provide the diagnostic test, prognostic test, and adjuvant treatment to support their health outcomes.
Level of adoption (i.e. list of customers/users, testimonials, etc.), if applicable
We have piloted the efforts in 20 patients in solid tumors with significant results published in Cell in 2020.
Impact (i.e. measurable outcomes), if applicable
Progression free survival, overall response rate, and value based care fulfillment.
List of Funding Sources (if applicable)
Boot strapped from from parent company PHAGE Corporation